Malignant Endocrine Neoplasm — Drugs

Malignant Endocrine Neoplasm — Drugs · CancerIndex

Regulatory

Approvals by jurisdiction

51 approval records across 2 jurisdictions, including tumor-agnostic approvals.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Vandetanib	US FDA	Thyroid Gland Medullary Carcinoma	CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 )	approved	Apr 6, 2011	openfda

Data updated 14 hours agoSource updated unknown

Curated evidence

Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.

Therapy	Evidence items (count)	Sensitivity / response	Resistance
Selpercatinib	18	14	4
Vemurafenib	5	5	0
Larotrectinib	4	4	0
Dabrafenib	3	3	0
Pralsetinib	3	0	3
Axitinib	2	0	2
Cabozantinib	2	2	0
Cisplatin	2	2	0
Dasatinib	2	2	0
Irinotecan	2	2	0
Motesanib	2	0	2
Olaparib	2	2	0
Pembrolizumab	2

Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.